Tim Cooksley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tim Cooksley has a total of 425 co-authors. Here are the top co-authors by number of shared publications:
- Mikkel Brabrand
Department of Emergency Medicine, Odense University Hospital, Odense, Denmark
14 shared publications - John Kellett
School of Clinical and Biomedical Sciences, University of Greater Manchester , A676 Deane Rd, Bolton BL3 5AB, Manchester
9 shared publications - Christian Peter Subbe
Advanced Internal Medicine, Woodlands Hospital, Singapore; North Wales Medical School, Bangor University, Bangor, UK
8 shared publications - Mark Holland
School of Clinical and Biomedical Sciences, University of Bolton, Bolton, UK
8 shared publications - Bernardo Leon Rapoport
The Medical Oncology Centre of Rosebank, Johannesburg, South Africa
7 shared publications - Douglas Buckner Johnson
Vanderbilt University Medical Center, Nashville, USA
7 shared publications
Latest Publications
- Open Access
- 12 October 2026
- Published by Elsevier in Journal of Infection
Management of suspected infectious and autoimmune encephalitis in adults – National Guidelines from the United Kingdom Joint Societies
- 12 October 2026
- Published by Elsevier in Journal of Infection
Open AccessManagement of suspected infectious and autoimmune encephalitis in adults – National Guidelines from the United Kingdom Joint Societies
- 12 September 2026
- Published by Elsevier in European Journal of Cancer
- Vol. 248, 117054
Prophylactic use of G-CSFs to reduce neutropenia rates in patients treated with antibody–drug conjugates: A literature review
- 12 September 2026
- Published by Elsevier in European Journal of Cancer
- Vol. 248, 117054
Prophylactic use of G-CSFs to reduce neutropenia rates in patients treated with antibody–drug conjugates: A literature review
- Open Access
- 29 July 2026
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 34 (8) , 813
Febrile neutropenia in patients treated with chemotherapy/immune checkpoint inhibition: a MASCC consensus statement
- 29 July 2026
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 34 (8) , 813
Open AccessFebrile neutropenia in patients treated with chemotherapy/immune checkpoint inhibition: a MASCC consensus statement
- Open Access
- 15 July 2025
- Published by Elsevier in The Breast
- Vol. 83, 104536
Acute presentations in neoadjuvant chemotherapy/immune checkpoint inhibition for triple negative breast cancer: experiences and impact from real-world data
- 15 July 2025
- Published by Elsevier in The Breast
- Vol. 83, 104536
Open AccessAcute presentations in neoadjuvant chemotherapy/immune checkpoint inhibition for triple negative breast cancer: experiences and impact from real-world data
- 2 June 2025
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 33 (6) , 1-5
Immune checkpoint inhibitor-related myasthenia gravis, myocarditis and myositis: further insights
- 2 June 2025
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 33 (6) , 1-5
Immune checkpoint inhibitor-related myasthenia gravis, myocarditis and myositis: further insights
- 17 January 2025
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 33 (2) , 1-4
Low-risk febrile neutropenia: does combined chemotherapy/immune checkpoint inhibitor necessitate a change in approach?
Purpose Management of patients with low-risk febrile neutropenia in an outpatient setting guided by the MASCC score is proven to be safe and effective. Most patients on ambulatory low-risk febrile neutropenia pathways are undergoing treatment for breast cancer. Recent data has shown benefit of the addition of immune checkpoint inhibitor therapy to cytotoxic chemotherapy in the neoadjuvant setting for patients with early triple-negative breast cancer. We examined whether the addition of ICI therapy altered the clinical severity of febrile neutropenia in this cohort and the ability to manage these patients in an ambulatory setting. Methods An observational analysis was performed at a specialist oncology hospital in the North West of England. We compared patients with triple negative breast cancer presenting with febrile neutropenia following treatment with PC-EC/pembrolizumab to those treated with PC-EC in the neoadjuvant setting. Results In the study periods, 152 patients received PC-EC and 151 PC-EC/Pembro. Twenty-five patients presented with FN in the PC-EC/Pembro group compared to 16 in those receiving PC-EC (16% vs 11%, p > 0.05). Patients with febrile neutropenia treated with PC-EC/Pembro had more severe clinical presentations as assessed by the MASCC score (18 vs 24; p = 0.01), had worse physiological parameters (NEWS2 at presentation 3 vs 2; p = 0.023) and had a longer length of hospital stay (median 5 days vs 0 days; p = 0.044). There were no deaths at 30 or 90 days in either cohort. Conclusion Triple-negative breast cancer patients receiving neoadjuvant pembrolizumab in addition to PC-EC appear to have more severe presentations with febrile neutropenia. This may necessitate greater caution in pathways for ambulatory management for this cohort.
- 17 January 2025
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 33 (2) , 1-4
Low-risk febrile neutropenia: does combined chemotherapy/immune checkpoint inhibitor necessitate a change in approach?
Purpose Management of patients with low-risk febrile neutropenia in an outpatient setting guided by the MASCC score is proven to be safe and effective. Most patients on ambulatory low-risk febrile neutropenia pathways are undergoing treatment for breast cancer. Recent data has shown benefit of the addition of immune checkpoint inhibitor therapy to cytotoxic chemotherapy in the neoadjuvant setting for patients with early triple-negative breast cancer. We examined whether the addition of ICI therapy altered the clinical severity of febrile neutropenia in this cohort and the ability to manage these patients in an ambulatory setting. Methods An observational analysis was performed at a specialist oncology hospital in the North West of England. We compared patients with triple negative breast cancer presenting with febrile neutropenia following treatment with PC-EC/pembrolizumab to those treated with PC-EC in the neoadjuvant setting. Results In the study periods, 152 patients received PC-EC and 151 PC-EC/Pembro. Twenty-five patients presented with FN in the PC-EC/Pembro group compared to 16 in those receiving PC-EC (16% vs 11%, p > 0.05). Patients with febrile neutropenia treated with PC-EC/Pembro had more severe clinical presentations as assessed by the MASCC score (18 vs 24; p = 0.01), had worse physiological parameters (NEWS2 at presentation 3 vs 2; p = 0.023) and had a longer length of hospital stay (median 5 days vs 0 days; p = 0.044). There were no deaths at 30 or 90 days in either cohort. Conclusion Triple-negative breast cancer patients receiving neoadjuvant pembrolizumab in addition to PC-EC appear to have more severe presentations with febrile neutropenia. This may necessitate greater caution in pathways for ambulatory management for this cohort.
- Open Access
Provision of medical Same Day Emergency Care services within the UK: analysis from the Society for Acute Medicine Benchmarking Audit
Aim To evaluate current provision of medical Same Day Emergency Care (SDEC) services within the UK, and current utilisation of these pathways in the assessment of unplanned medical attendances. Design Survey data was used from the Society for Acute Medicine Benchmarking Audit (SAMBA), including anonymised patient-level data collected annually using a day of care survey Setting Hospitals accepting unplanned medical attendances within the UK, 2019-2023. Participants: 34,948 unplanned and 4,342 planned attendances, across 188 hospital sites Results 29.8% of unplanned medical attendances received their initial medical assessment within SDEC services, with the proportion increasing over time. 82.4% of patients assessed in SDEC services were discharged without overnight admission. Assessment in SDEC services was less likely in male patients, patients with frailty, and older adults (all pConclusions Medical SDEC provides assessment for one third of patients seen through acute medicine services. Although the proportion of patients assessed within SDEC is increasing, further innovation and improvements are needed to ensure appropriate patients access this service. Strengths and limitations of this study -Medical same day emergency care (SDEC) has been widely adopted in the UK to deliver care to patients without overnight hospital admission, however there is limited evidence guiding development of this service. -This study compares hospital-level data describing SDEC service structure and processes, and patient level data for over 35,000 patient attendances at 188 hospitals in the UK. -This is the largest evaluation of medical SDEC to date and demonstrates an increase in the use of SDEC for medical patients nationally. -The participation rate was higher amongst hospitals in England compared to the other three UK nations, which may limit generalisability.
Open AccessProvision of medical Same Day Emergency Care services within the UK: analysis from the Society for Acute Medicine Benchmarking Audit
Aim To evaluate current provision of medical Same Day Emergency Care (SDEC) services within the UK, and current utilisation of these pathways in the assessment of unplanned medical attendances. Design Survey data was used from the Society for Acute Medicine Benchmarking Audit (SAMBA), including anonymised patient-level data collected annually using a day of care survey Setting Hospitals accepting unplanned medical attendances within the UK, 2019-2023. Participants: 34,948 unplanned and 4,342 planned attendances, across 188 hospital sites Results 29.8% of unplanned medical attendances received their initial medical assessment within SDEC services, with the proportion increasing over time. 82.4% of patients assessed in SDEC services were discharged without overnight admission. Assessment in SDEC services was less likely in male patients, patients with frailty, and older adults (all pConclusions Medical SDEC provides assessment for one third of patients seen through acute medicine services. Although the proportion of patients assessed within SDEC is increasing, further innovation and improvements are needed to ensure appropriate patients access this service. Strengths and limitations of this study -Medical same day emergency care (SDEC) has been widely adopted in the UK to deliver care to patients without overnight hospital admission, however there is limited evidence guiding development of this service. -This study compares hospital-level data describing SDEC service structure and processes, and patient level data for over 35,000 patient attendances at 188 hospitals in the UK. -This is the largest evaluation of medical SDEC to date and demonstrates an increase in the use of SDEC for medical patients nationally. -The participation rate was higher amongst hospitals in England compared to the other three UK nations, which may limit generalisability.
- Open Access
- 21 February 2024
- Published by Elsevier in European Journal of Cancer
- Vol. 202, 113949
Thyroid dysfunction after immune checkpoint inhibitors in a single-centre UK pan-cancer cohort: A retrospective study
- 21 February 2024
- Published by Elsevier in European Journal of Cancer
- Vol. 202, 113949
Open AccessThyroid dysfunction after immune checkpoint inhibitors in a single-centre UK pan-cancer cohort: A retrospective study
- Open Access
- 16 January 2024
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
- Vol. 117 (5) , 373-374
Immune checkpoint inhibitor-related myasthenia gravis, myositis and myocarditis: a triad but not at the same time?
Immune checkpoint inhibitor-related myasthenia gravis and its overlap syndrome with myocarditis and myositis occur early after initiation of therapy and are associated with significant mortality. 1, 2 The clinical course of immune checkpoint inhibitor-mediated myasthenia gravis tends to be more aggressive than its de novo counterparts and management strategies must be adapted to recognize this. We describe a presentation of this condition, which may offer further insights into its disease course and management.
- 16 January 2024
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
- Vol. 117 (5) , 373-374
Open AccessImmune checkpoint inhibitor-related myasthenia gravis, myositis and myocarditis: a triad but not at the same time?
Immune checkpoint inhibitor-related myasthenia gravis and its overlap syndrome with myocarditis and myositis occur early after initiation of therapy and are associated with significant mortality. 1, 2 The clinical course of immune checkpoint inhibitor-mediated myasthenia gravis tends to be more aggressive than its de novo counterparts and management strategies must be adapted to recognize this. We describe a presentation of this condition, which may offer further insights into its disease course and management.
- 25 October 2023
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 31 (11) , 1-3
The need for ambulatory emergency oncology: exemplified by the management of immune checkpoint inhibitor toxicity
Cancer patients seeking emergency care can be vulnerable in increasingly overcrowded Emergency Departments and timely delivery of care is often aspirational rather than reality in many acute care systems. Ambulatory emergency care and its various international models are recognized as contributing to the safety and sustainability of emergency care services. This schema can logically be extended to the emergency oncology setting. The recent proliferation of immune checkpoint inhibitors (ICIs) has led to another opportunity for the management of oncologic complications in the ambulatory emergency care setting. More nuanced risk stratification of currently perceived high-risk toxicities may also afford the opportunity to personalize acute management. Virtual wards, which predominantly provide virtual monitoring only, and hospital at home services, which provide more comprehensive in-person assessment and interventions, may be well suited to supporting care for ICI toxicity alongside hospital-based assessment. Emergency management guidelines for immune-mediated toxicities will increasingly need to be both pragmatic and deliverable, especially as larger numbers of patients will present outside cancer centers. Identifying and modelling those suitable for emergency ambulatory care is integral to achieving this.
- 25 October 2023
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 31 (11) , 1-3
The need for ambulatory emergency oncology: exemplified by the management of immune checkpoint inhibitor toxicity
Cancer patients seeking emergency care can be vulnerable in increasingly overcrowded Emergency Departments and timely delivery of care is often aspirational rather than reality in many acute care systems. Ambulatory emergency care and its various international models are recognized as contributing to the safety and sustainability of emergency care services. This schema can logically be extended to the emergency oncology setting. The recent proliferation of immune checkpoint inhibitors (ICIs) has led to another opportunity for the management of oncologic complications in the ambulatory emergency care setting. More nuanced risk stratification of currently perceived high-risk toxicities may also afford the opportunity to personalize acute management. Virtual wards, which predominantly provide virtual monitoring only, and hospital at home services, which provide more comprehensive in-person assessment and interventions, may be well suited to supporting care for ICI toxicity alongside hospital-based assessment. Emergency management guidelines for immune-mediated toxicities will increasingly need to be both pragmatic and deliverable, especially as larger numbers of patients will present outside cancer centers. Identifying and modelling those suitable for emergency ambulatory care is integral to achieving this.